Episode Player

Could opioids be silently undermining cancer immunotherapy?

This week, Justin Chickles — CEO and co-founder of Glycyx Therapeutics — explains how his team is tackling this overlooked challenge with axelopran, a breakthrough therapy now advancing to Phase 2 trials.

From his early career at Johnson & Johnson to leading multiple startups, Justin offers a rare, insider’s perspective on driving biotech innovation from concept to clinic. If you’re interested in cutting-edge oncology, translational science, and biotech entrepreneurship, you won’t want to miss this episode.